International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece.

Diabetes Technol. Ther., Sep;13(9):967-79 (2011)

Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study.

Diabetes Obes Metab., Nov;13(11):1020-7 (2011)

Glycemic control and cardiovascular mortality.

Curr Opin Endocrinol Diabetes Obes., Apr;18(2):104-9 (2011)

Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues.

Diabetes Care., Dec;33(12):2722-4 (2010)

More reasons to say goodbye to glyburide.

J. Clin. Endocrinol. Metab., Nov;95(11):4867-70 (2010)

Therapy: What evidence should guide the use of thiazolidinediones?

Nat Rev Endocrinol., Nov;6(11):600-2 (2010)

Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Circulation., Aug;122(8):844-6 (2010)

Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.

Diabetes Care., May;33(5):983-90 (2010)

Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy.

Arch. Ophthalmol., Mar;128(3):312-8 (2010)

Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor.

Diabetes Care., Feb;31 Suppl 2:S125-30 (2008)

Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).

Am. Heart J., Jan;155(1):26-32, 32.e1-6 (2008)

Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary.